0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TRAIL

TRAIL

Brief Information

Name:Tumor necrosis factor ligand superfamily member 10
Target Synonym:CD253,Apo-2 ligand,TNFSF10,TNF Superfamily Member 10,APO2L,Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta,Tumor Necrosis Factor Ligand Superfamily Member 10,Tumor Necrosis Factor (Ligand) Family, Member 10,TNF-Related Apoptosis Induc
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TRL-H5259 Human Human TRAIL / TNFSF10 Protein, Mouse IgG2a Fc Tag
TRL-H5259-structure
TRL-H5259-sds
TRL-H5259-elisa_1

Part of Bioactivity data

TRL-H5259-ELISA
Human TRAIL, Mouse IgG2a Fc TagHuman TRAIL, Mouse IgG2a Fc Tag (Cat. No. TRL-H5259) ELISA bioactivity

Immobilized Human Osteoprotegerin, His Tag (Cat. No. TNB-H5220) at 5 μg/mL (100 μL/well) can bind Human TRAIL, Mouse IgG2a Fc Tag (Cat. No. TRL-H5259) with a linear range of 0.8-13 ng/mL (QC tested).

Synonym Name

Apo-2L,TRAIL,CD253,TNFSF10,Apo-2 ligand

Background

TRAIL, also known as  TNFSF10, APO2L, Apo-2L, CD253, TL2, TRAIL, TNLG6A and TNF superfamily member 10. The TRAIL gene as a drug target, induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
INBRX-109 INBRX-109 Phase 1 Clinical Inhibrx Chondrosarcoma; Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Mesothelioma; Sarcoma, Ewing; Sarcoma; Colorectal Neoplasms Details

This web search service is supported by Google Inc.

totop